Phase 2 N=248 Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Mesothelioma
Primary: Progression-free Survival (PFS), [95% CI] — 4.3; 4.5 months — p=0.859125
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=6 Time Restricted Eating Pilot - Bariatrics
Time Restricted Feeding
Primary: Weight — -.07 kg
Phase 2 N=27 Trial of TRC105 and Sorafenib in Patients With HCC
Hepatocellular Carcinoma
Primary: Number of Patients Who Experience Dose Limiting Toxicities by Dose Level — 1; 0 Participants
N/A N=92 Neuroproprioceptive "Facilitation, Inhibition" and Brain Plasticity
Multiple Sclerosis
Primary: White Matter Integrity — 0.5023; 0.5168; 0.4747 score on a scale
Phase 1 N=52 Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
HIV Infections
Primary: Number of Infants Who Died or Had Grade 3/4 Adverse Event Through 6 Weeks of Life — 2; 2; 4; 7 Participants
Phase 2 N=25 Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
Rosacea
Primary: Relative Trypsin-like Enzyme Activity — 1.10 percentage of baseline
N/A N=43 Internet-Delivered Positive Affect Program in Managing Emotion in Young Adult Cancer Survivors
Cancer Survivor
Primary: Acceptability - Mean Value — 8.81 score on a scale
Phase 2 N=45 B Cell Induction in Pediatric Lung Transplantation
Lung Transplant
Primary: Earliest Time to Any of the Following Events: Chronic Allograft Dysfunction, Listed for Retransplant or Death — NA; 703 Days — p=0.514
Phase 2 N=167 A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 — -23.0; -39.4; -61.7; -74.4 percent change — p=< 0.001
N/A N=199 Sleep Treatment Outcome Predictors: A Pilot Study (STOP-pilot)
Sleep Problem
Primary: Improvement in Insomnia Symptoms Following Online CBT — 2.98; 1.26; 4.69; 2.34 score on a scale
Phase 3 N=22 Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
SMA - Spinal Muscular Atrophy · Gene Therapy
Primary: Achievement of Independent Sitting for at Least 30 Seconds — 13 Participants — p=<0.0001
Phase 1 N=74 Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Solid Tumors
Primary: Percentage of Participants With Treatment-emergent Adverse Events (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel…
Phase 2 N=3 Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)
Post Traumatic Stress Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Clinician Administered PTSD Scale for DSM-5 (CAPS-5) — 2 Participants
N/A N=48 Study of Mobile Phone Delivered Intervention to Reduce Alcohol Consumption
Alcohol Abuse
Primary: Acceptability of Intervention to Patient — 23; 24 Participants
Phase 4 N=44 A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Schizophrenia · Schizoaffective Disorder · First Episode Psychosis
Primary: Percentage Of Days With Good Patch Coverage — 64.34; 62.99; 62.51; 63.37 percentage of days